Archive · 24 Jul 2026
Zota Healthcare CEO on US Tariffs
The US might put high taxes on generic drugs from India.
Dr. Sujit Paul, the CEO of Zota Healthcare, thinks Indian drug companies will still be the best in terms of price and quality.
He suggests that these companies should look for new markets, work more with US companies, and focus on making more complicated drugs.
This way, they can handle any problems caused by the US taxes.
The US may impose steep tariffs on generic drug imports from India.
Zota Healthcare CEO Dr. Sujit Paul believes Indian manufacturers will retain their cost and quality advantage.
Companies should diversify markets and expand US manufacturing partnerships.
Focus should be on complex generics and biosimilars.
The two-year window provides an opportunity for strategic adjustments.
- Who
- Dr. Sujit Paul, CEO of Zota Healthcare
- What
- Potential US tariffs on generic drug imports
- When
- Not specified
- Where
- United States and India
- Why
- To address potential disruptions in the Indian pharmaceutical industry
US Tariffs on Generics
Indian Generics Advantage
Impact of Tariffs
US Tariffs on Generics
The US may impose steep tariffs on generic drug imports, potentially disrupting the Indian pharmaceutical industry.
Indian Generics Advantage
Indian manufacturers will retain their cost and quality advantage despite potential tariffs.
Strategic Response
US Tariffs on Generics
The US tariffs could force Indian companies to rethink their export strategies.
Indian Generics Advantage
Indian companies should diversify markets, expand US manufacturing partnerships, and focus on complex generics and biosimilars.
- CEO
- Dr. Sujit Paul
- Company
- Zota Healthcare
- Potential Tariffs
- Steep tariffs on generic drug imports
- Indian Advantage
- Cost and quality advantage
- Strategic Recommendations
- Diversify markets, expand US partnerships, focus on complex generics and biosimilars